Previous close | 26.62 |
Open | 27.10 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 26.62 - 26.62 |
52-week range | 25.04 - 34.47 |
Volume | |
Avg. volume | 6,103 |
Market cap | 41.758B |
Beta (5Y monthly) | 0.54 |
PE ratio (TTM) | 36.97 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.24 (4.67%) |
Ex-dividend date | 28 Mar 2024 |
1y target est | N/A |
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).